Video

Examining 10-year postop data on epi-off CXL for keratoconus, ectasia

Author(s):

David Hutton,Alex Delaney-Gesing
Conferences|ASCRS

Steven Greenstein, MD, reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients.

Steven Greenstein, MD, of the Cornea and Laser Institute (Teaneck, NJ), reports on the 10-year postop data from an epi-off corneal collagen cross-linking treatment in keratoconus and ectasia patients who underwent laser refractive surgery.

Read the article: CXL effects remain generally stable 10 years post-treatment

See more ASCRS coverage

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
At the 2025 American Society of Cataract and Refractive Surgery (ASCRS) meeting, Seth Pantanelli, MD, speaks about the EyHance and enVista IOLs. Dr. Pantanelli is a professor of ophthalmology at Penn State College of Medicine in Hershey, Pennsylvania.
Related Content
Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia
June 12th 2025

Formosa Pharmaceuticals grants Harrow US commercial rights to clobetasol propionate ophthalmic suspension 0.05% (BYQLOVI), terminates deal with Eyenovia

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial
June 11th 2025

Q&A: Justis P. Ehlers, MD, on the Phase 1 HELIOS NPDR trial

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

(Image credit: AdobeStock/upnowgraphics) Ophthalmology Times: AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium
June 9th 2025

AMD, AI, and the future of eye imaging: Inside the 2025 International SPECTRALIS Symposium

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids
June 9th 2025

Q&A: Siegfried Priglinger, MD, on the long-term outcomes of gene therapy in preschool kids

© 2025 MJH Life Sciences

All rights reserved.